A phase 1, randomized, double-blind, placebo-controlled, dose-escalation study to evaluate the safety, tolerability, immunogenicity, and viral shedding of MEDI-534, a live, attenuated intranasal vaccine against respiratory syncytial virus (RSV) and parainfluenza virus type 3, in healthy children 6 to less than 24 months of age.
Phase of Trial: Phase I
Latest Information Update: 18 Jul 2012
At a glance
- Drugs MEDI 534 (Primary)
- Indications Parainfluenza virus infections; Respiratory syncytial virus infections
- Focus Adverse reactions
- Sponsors MedImmune
- 15 Sep 2011 Results published in the Pediatric Infectious Disease Journal.
- 03 May 2011 Results presented at the 2011 Annual Meeting of the Pediatric Academic Societies.
- 11 Mar 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.